Stopping semaglutide treatment may do more than slow weight loss. The best available clinical evidence shows that the cardiovascular benefits tied to semaglutide persist while patients remain on therapy, with major heart events reduced during treatment in large trials, but weight regain after discontinuation is common and can reverse some of the metabolic improvements that help protect the heart. The concern is not that stopping Ozempic or Wegovy causes an immediate cardiac event on its own, but that ending treatment may remove a therapy shown to lower cardiovascular risk in the right patients.
The strongest evidence comes from the SELECT cardiovascular outcomes trial, which studied 17,604 adults age 45 or older with overweight or obesity and established cardiovascular disease, but without diabetes. In that trial, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, by 20% versus placebo. The event rate was 6.5% in the semaglutide group compared with 8.0% in the placebo group. Those results supported the U.S. Food and Drug Administration’s March 8, 2024 approval of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
That matters for any headline suggesting that “quitting Ozempic could hit your heart hard.” The data-backed version is narrower and more precise: if semaglutide lowers cardiovascular risk while a patient is taking it, then stopping treatment may also mean losing some of that protection over time. That is especially relevant for people who qualified for treatment because they had obesity, overweight, diabetes, or established cardiovascular disease. The FDA’s expanded Wegovy label was based on measured reductions in hard outcomes, not just weight loss or blood sugar changes.
The available evidence does not show that every person who stops Ozempic will suddenly face a heart emergency. It does show that semaglutide’s benefits are linked to ongoing treatment. In the SELECT trial and related reporting, patients remained on therapy for years, and the cardiovascular benefit was observed during that treatment period. That is a different claim from saying the benefit remains fully intact after discontinuation.
Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for chronic weight management, but both contain the same active ingredient. The heart-risk discussion is tied to semaglutide itself, not just the brand name. In people with obesity or overweight and cardiovascular disease, semaglutide appears to improve several factors associated with heart health, including body weight, blood sugar regulation, and in some studies blood pressure and inflammatory markers. When treatment stops, some of those gains can fade.
One of the clearest post-treatment signals is weight regain. A 2026 report summarizing a review of 37 studies found that people taking common GLP-1 drugs lost an average of 33 pounds while on treatment but regained about 22 pounds within a year of stopping. That figure is not a direct measure of heart attacks or strokes, but it matters because excess weight is a major cardiovascular risk factor. If a patient regains much of the lost weight after discontinuing therapy, the metabolic and cardiovascular profile that improved on treatment may worsen again.
Earlier semaglutide studies also found that treatment benefits depend on continuation. In the STEP program, patients on semaglutide achieved substantially greater weight loss than placebo during active treatment. The Journal of Medical Ethics review published in 2025 cited STEP 5 data showing average weight loss of 15.2% with semaglutide versus 2.6% with placebo over two years. That same review also highlighted the SELECT finding that semaglutide reduced major cardiac events by 20%, while noting that the mechanisms likely include more than weight loss alone.
The practical implication is straightforward. If semaglutide is helping lower body weight, improve cardiometabolic markers, and reduce major cardiovascular events in high-risk patients, then stopping it may allow those risk factors to drift back in the wrong direction. That is the core reason researchers and clinicians treat obesity and cardiometabolic disease as chronic conditions that often require long-term management rather than short-term medication use.
The FDA’s March 2024 decision was a turning point because it formally recognized semaglutide’s cardiovascular benefit in a defined patient group. Wegovy became the first treatment approved specifically to reduce the risk of serious heart problems in adults with obesity or overweight and established cardiovascular disease. The agency said the approval was based on the reduction in major adverse cardiovascular events seen in the trial, with 6.5% of Wegovy-treated participants experiencing a primary endpoint event versus 8.0% on placebo.
That approval also had insurance implications. In March 2024, federal guidance opened the door for Medicare Part D plans to cover anti-obesity drugs like Wegovy when they are approved for an additional medically accepted use, such as reducing cardiovascular risk in eligible heart patients. Associated Press reported at the time that the policy could expand access for patients who have both heart disease and obesity or overweight.
This matters because discontinuation is often driven by cost, coverage gaps, side effects, or supply issues rather than a doctor’s view that treatment is no longer needed. If patients stop because they cannot access the drug, the issue becomes more than weight regain. It becomes a continuity-of-care problem for a therapy that now carries an FDA-recognized cardiovascular indication in some adults.
The evidence base is strong for semaglutide’s cardiovascular benefit during treatment, but thinner on what happens to hard cardiac outcomes after discontinuation. That distinction is important. The available sources support three facts: semaglutide lowers major cardiovascular event risk in certain patients while they are taking it; weight often returns after stopping GLP-1 therapy; and the mechanisms of cardiovascular benefit may extend beyond weight loss alone. What remains less certain is the exact size and timing of any increase in heart risk after discontinuation in different patient groups.
Researchers have suggested that semaglutide’s heart benefits may not be explained solely by weight reduction. Reporting on the SELECT data noted that cardiovascular improvement appeared even beyond what weight loss alone would predict. The American Heart Association summary and related coverage pointed to the possibility of additional mechanisms, though those mechanisms are still being studied.
That means stopping treatment could theoretically remove more than one layer of protection. A patient may regain weight, see blood sugar control worsen, or lose other favorable effects that helped reduce cardiovascular strain. But the responsible reading of the evidence is that this is an inference from trial and follow-up data, not a proven one-size-fits-all outcome for every person who discontinues Ozempic or Wegovy.
Many headlines use “Ozempic” as shorthand for semaglutide, but the cardiovascular approval specifically applies to Wegovy, the higher-dose semaglutide product indicated for chronic weight management and, since March 2024, cardiovascular risk reduction in certain adults. Ozempic remains approved for type 2 diabetes, though clinicians may prescribe drugs off-label in some cases. The active ingredient is the same, but the labeled uses are not identical.
For readers in the United States, that distinction affects how to interpret the phrase “quitting Ozempic.” If a person is taking Ozempic for diabetes, stopping it may affect blood sugar control and indirectly influence cardiovascular risk through diabetes management. If a person is taking Wegovy and qualifies under the FDA’s cardiovascular indication, stopping may also mean stepping away from a therapy specifically shown to reduce major heart events in that population. Those are related but not identical clinical scenarios.
The same caution applies to comparisons with other GLP-1 drugs. The American College of Cardiology announced in March 2025 that the SOUL trial found oral semaglutide reduced cardiovascular events by 14% at four years in people with type 2 diabetes and atherosclerotic cardiovascular disease and or chronic kidney disease. That supports a broader cardiovascular role for semaglutide across formulations, but it does not replace the specific evidence base for Wegovy in obesity and established cardiovascular disease.
The people most likely to be affected are those who started semaglutide because they already had elevated cardiovascular risk. In SELECT, that meant adults with overweight or obesity plus established cardiovascular disease. In diabetes care, it can include patients whose blood sugar control, weight, and cardiovascular profile improve on semaglutide and may worsen after discontinuation.
Patients who stop after achieving substantial weight loss may assume the benefit is locked in. The evidence does not support that assumption. The 2026 review summarized by HealthDay found that much of the lost weight can return within a year of stopping GLP-1 therapy. Since obesity is a chronic disease and cardiovascular risk accumulates over time, rebound weight gain is not a cosmetic issue. It can be clinically meaningful.
There is also a medication-management angle. A February 2025 report on analyses from the STEP trials said semaglutide users were more likely than placebo users to discontinue or reduce antihypertensive and lipid-lowering medications, and 13.7% of semaglutide users without diabetes reached hypertension remission at 68 weeks versus 6.2% on placebo. If some patients improve enough on treatment to reduce other medications, stopping semaglutide later could complicate that balance and require reassessment of blood pressure, lipids, or glucose control.
The main takeaway is not panic. It is continuity. Semaglutide’s cardiovascular benefit is supported by large, high-quality evidence during active treatment, and the FDA has already acted on that evidence for Wegovy. At the same time, post-treatment data show that stopping GLP-1 therapy often leads to significant weight regain, which can erode some of the cardiometabolic progress made on the drug.
For patients, the safest interpretation is that stopping Ozempic or Wegovy should be a medical decision, not a casual one. Anyone taking semaglutide for diabetes, obesity, or cardiovascular risk reduction should talk with a clinician before discontinuing, especially if the reason is side effects, cost, or supply. The question is not only whether weight will return, but whether blood sugar, blood pressure, and overall cardiovascular risk will change after treatment ends.
The headline claim that stopping Ozempic may raise heart risks is directionally supported by the evidence, but only when stated carefully. Large clinical trials show semaglutide reduces major cardiovascular events while patients are on treatment, and follow-up evidence shows that stopping GLP-1 therapy often leads to substantial weight regain. What researchers have not yet fully quantified is the exact post-discontinuation heart-risk increase for each patient group. For now, the clearest conclusion is that semaglutide’s heart benefits are tied to ongoing therapy, and stopping it may mean giving up part of that protection.
Q: Does stopping Ozempic immediately cause heart problems?
A: The current evidence does not show that stopping Ozempic or Wegovy triggers an immediate heart event by itself. What the data do show is that semaglutide lowers cardiovascular risk during treatment in certain patients, and stopping may remove that benefit over time.
Q: What study linked semaglutide to lower heart risk?
A: The key study is the SELECT trial, which enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. It found semaglutide reduced major adverse cardiovascular events by 20%, with event rates of 6.5% versus 8.0% for placebo.
Q: Why could quitting semaglutide affect heart health?
A: The main reason is that benefits achieved on treatment can fade after discontinuation. A 2026 review of 37 studies found people on common GLP-1 drugs regained about 22 pounds within a year after stopping, after losing an average of 33 pounds during treatment.
Q: Is Ozempic approved to reduce heart attack and stroke risk?
A: In the United States, the March 8, 2024 cardiovascular-risk reduction approval applies to Wegovy, not Ozempic. Both contain semaglutide, but Wegovy’s label specifically includes reducing cardiovascular death, heart attack, and stroke in certain adults with cardiovascular disease and obesity or overweight.
Q: Should patients stop Ozempic or Wegovy once they lose weight?
A: The evidence does not support assuming the benefit will fully persist after stopping. Because obesity and cardiometabolic disease are chronic conditions, discontinuation should be discussed with a clinician, especially for patients using semaglutide for diabetes control or cardiovascular risk reduction.
The post Stopping Ozempic May Raise Heart Risks, New Research Shows appeared first on thedigitalweekly.com.
Earning extra income on the side has never been easier, but the tax side of…
Follow the Artemis 2 Crew as they become the first humans to travel beyond Earth…
Get the latest on Iran Says It Hit Oracle Facilities in UAE, what happened, why…
Watch Rocky from ‘Project Hail Mary’ sleep with the perfect accompaniment. Enjoy this soothing scene…
Celebrate the Deadpool & Wolverine moment designed for you to gawk at Hugh Jackman’s chiseled…
Follow NASA’s Artemis 2 mission blasts off as astronauts begin their crewed Moon journey. Get…
